

Program Schedule

Sunday 22 September 2024

15:45	Opening / Registration
16:00 – 16:15	Welcome Speech - Philip Thompson (Monash University, Parkville, Australia)
16:15 – 17:00	Keynote Lecture: (Introduced by Philip Thompson, Monash University, Parkville, Australia) Efstratios Stratikos (National and Kapodistrian University of Athens, Greece) <i>"The cautionary tale of three inhibitors"</i>
17:00 – 18:45	Welcome drinks and canapes

Plenary- Efstratios Stratikos "The cautionary tale of three inhibitors"



Efstratios Stratikos is an Associate Professor of Biochemistry and the Director of the Laboratory of Biochemistry of the Department of Chemistry at the National and Kapodistrian University of Athens, Greece. He is also an Adjunct Researcher at the National Centre for Scientific Research "Demokritos". After obtaining a degree in Chemistry from the University of Athens in 1994, he continued his studies in the USA, at the University of Illinois Medical School in Chicago, where he obtained a PhD in Biochemistry in 1999. From 1999 to 2004 he was a postdoctoral researcher at Harvard University in Boston, USA. From 2005 to 2020 he worked as a researcher at the National Centre for Scientific Research "Demokritos" where he was promoted to the rank of Research Director in 2014 as head of the Protein Chemistry Laboratory. Since 2020 he has been working at the National and Kapodistrian University of Athens. His

research interests focus on the study of proteins and their role in human disease and in particular on the molecular mechanisms of the human immune system.

Monday 23 September 2024

Session 1: Biochemistry/Chemistry/Structural Biology	
9:00 - 9:15	Introduction: Johan Gising (<i>Uppsala University, Sweden</i>)
9:15 – 9:45	Talk 1: Galatea Georgaki (<i>National and Kapodistrian University of Athens, Greece</i>) <i>Targeting an allosteric site in Insulin-regulated Aminopeptidase for the discovery of selective inhibitors</i>
9:45 – 10:15	Talk 2: Sharathna Puthiyaparambath (<i>Uppsala University, Sweden</i>) <i>Inhibition of Insulin-Regulated Aminopeptidase by Imidazo [1,5-α]pyridines-Synthesis and Evaluation</i>
10:15 – 10:45	Talk 3: Nour Karroum (<i>University of Lille, France</i>) <i>Discovery of novel and selective IRAP inhibitors</i>
10:45 – 11:15	Morning Tea Break
11:15 – 11:45	Talk 4: Marcus Söderström (<i>Uppsala University, Sweden</i>) <i>Benzylhydroxamic Acids as Inhibitors of Insulin Regulated Aminopeptidase (IRAP)</i>
11:45 – 12:15	Talk 5: Philip Thompson (<i>Monash University, Parkville, Australia</i>) <i>The Mystery of Angiotensin IV</i>
12:15 – 12:45	Panel Discussion: Mats Larhed (<i>Uppsala University, Sweden</i>) and Efstratios Stratikos (<i>National and Kapodistrian University of Athens, Greece</i>) <i>"Where to next?"</i>
12:45 – 13:45	Lunch Break
Session 2: IRAP in the CNS	
13:45 – 14:00	Introduction: Alfhild Gronbladh (<i>Uppsala University, Sweden</i>)
14:00 – 14:30	Talk 6: Weizhi Xu (<i>University of Queensland, Australia</i>) <i>Anticonvulsant effects of the IRAP inhibitor HFI-419 in mice may be explained by improved Glut4 dependent glucose uptake in neurons</i>
14:30 – 15:00	Talk 7: Frida Stam (<i>Uppsala University, Sweden</i>) <i>Inhibition of IRAP enhance the expression of pro-cognitive markers drebrin and MAP2 in primary neuronal cells</i>
15:00 – 15:30	Afternoon Tea Break
15:30 – 16:00	Talk 8: Pat Kehoe (<i>University of Bristol, UK</i>) <i>cRAS and rRAS imbalance in Alzheimer's disease - where does IRAP fit in?</i>
16:00 – 16:30	Talk 9: Siew Yeen Chai (<i>Monash University, Clayton, Australia</i>) <i>Role of IRAP in development</i>
16.30 – 17.00	Panel Discussion - Alfhild Gronbladh (<i>Uppsala University, Sweden</i>) and Karin Borges (<i>University of Queensland, Australia</i>) <i>"What does IRAP do in the brain?"</i>

Tuesday 24 September 2024

	Session 1: Immune Function / Trafficking
9:00 - 9:15	Introduction: Peter Van Endert (<i>Universite de Paris, France</i>)
9:15 – 9:45	Talk 1: Mathilde Nugue (<i>Universite de Paris, France</i>) <i>Activating FcγR function depends on endosomal-signaling platforms</i>
9:45 – 10:15	Talk 2: Mirjana Weimershaus (<i>Universite de Paris, France</i>) <i>IRAP is required for exocytic trafficking of pro-inflammatory cytokines</i>
10:15 – 10:45	Talk 3: Alice Senni (<i>Universite de Paris, France</i>) <i>The role of the IRAP compartment in cross-presentation: deciphering its molecular dynamics with TurboID</i>
10:45 – 11:15	Morning Tea Break
11:15 – 11:45	Talk 4: Irini Evnouchidou (<i>Universite de Paris, France</i>) <i>IRAP endosomal targeting for CAR T immunotherapy amelioration</i>
11:45 – 12:15	Talk 5: Chrishan Samuel (<i>Monash University, Clayton, Australia</i>) <i>Evaluating the interaction between IRAP and the NLRP3 inflammasome</i>
12:15 – 12:45	Panel discussion: Mirjana Weimershaus and Peter van Endert (<i>Universite de Paris, France</i>) <i>"IRAP regulates vesicular trafficking?"</i>
12:45 – 13:45	Lunch Break
	Session 2: CVD Keynote (Introduced by Robert Widdop, <i>Monash University, Clayton, Australia</i>)
13:45 – 14:30	Keynote: Louise Burrell (<i>University of Melbourne, Austin Health, Australia</i>) <i>"Clinical potential of anti-fibrotic agents in cardiovascular and renal diseases"</i>

Plenary- Louise Burrell- Clinical potential of anti-fibrotic agents in cardiovascular and renal diseases



Prof Louise Burrell is an active clinician-researcher with specialty training in Endocrinology and Internal Medicine and a significant track record of translational research in cardiovascular disease and related conditions. She is a Professor of Medicine at the University of Melbourne, Head of the Cardiovascular Research Group, and an Honorary Professor of Medicine at Dundee University. Her research program investigates the pathophysiology and treatment of cardiovascular disease with work that spans laboratory science and clinical research. She is internationally known for contributions and leadership in regard to the understanding and management of cardiovascular disease, particularly as it relates to the renin angiotensin system. She has a particular interest in role of ACE2 as a biomarker of risk in heart and kidney disease. She also has significant experience in randomised clinical trials, and recently led a large trial that studied the effect of climate on hospital admissions, and was involved in another that repurposed existing medications to reduce severe acute respiratory distress in patients with COVID-19.

14:30 – 15:00	Talk 6: Tracey Gaspari (Monash University, Clayton, Australia) <i>Targeting IRAP in treatment of diabetes-induced cardiovascular disease</i>
15:00 – 15:30	Afternoon Tea Break
15:30 – 16:00	Talk 7: Robert Widdop (Monash University, Clayton, Australia) <i>Role of AT2R in the anti-fibrotic effects of IRAP inhibitors</i>
16:00 – 16:30	Talk 8: Roy Kong (Inosi Therapeutics, Melbourne, Australia) <i>Anti-fibrotic drugs and assays</i>
16:30 – 17:00	Panel Discussion: Tracey Gaspari (Monash University, Clayton, Australia) and Muscha Steckelings (University of Southern Denmark, Denmark) <i>"Anti-inflammatory, anti-fibrotic effects of IRAP inhibitors"</i>
19:00	Conference Dinner: ILL Dek Italian Bistrot

Wednesday 25 September 2024

	Session 1: Bioassays/Biomarkers
9:00 - 9:25	Introduction: Serge Bottari (Grenoble-Alps University) <i>IRAP - perspectives in disease and therapeutics</i>
9:25 – 9:50	Talk 1: Siew Yeen Chai (Monash University, Clayton, Australia) <i>Development of IRAP Elisa</i>
9:50 – 10:20	Talk 2: Paul Gard (Brighton University, UK) <i>Urine and serum IRAP activity as a potential biomarker of foetal alcohol spectrum disorder</i>
10:20 – 10:45	Talk 3: Robert Widdop (Monash University, Clayton, Australia) <i>In vitro & in vivo IRAP activity assays</i>
10:45 – 11:15	Morning Tea Break
11:15 – 11:45	Talk 4: Philip Thompson (Monash University, Parkville, Australia) <i>Measuring IRAP cleavage of oxytocin and vasopressin and derivatives</i>
11:45 – 12:15	Panel Discussion: Paul Gard (Brighton University, UK) and Philip Thompson (Monash University, Parkville, Australia) <i>"What substrates for which assays"?</i>
12:15 – 12:45	Conference close: Siew Yeen Chai (Monash University, Clayton, Australia) and Anders Hallberg Uppsala University, Sweden) <ul style="list-style-type: none"> ➤ Sharing resources ➤ Collaborative international grants ➤ Next meeting?